An immunologic model for rapid vaccine assessment -- a clinical trial in a test tube.
While the duration and size of human clinical trials may be difficult to reduce, there are several parameters in pre-clinical vaccine development that may be possible to further optimise. By increasing the accuracy of the models used for pre-clinical vaccine testing, it should be possible to increase the probability that any particular vaccine candidate will be successful in human trials. In addition, an improved model will allow the collection of increasingly more-informative data in pre-clinical tests, thus aiding the rational design and formulation of candidates entered into clinical evaluation. An acceleration and increase in sophistication of pre-clinical vaccine development will thus require the advent of more physiologically-accurate models of the human immune system, coupled with substantial advances in the mechanistic understanding of vaccine efficacy, achieved by using this model. We believe the best viable option available is to use human cells and/or tissues in a functional in vitro model of human physiology. Not only will this more accurately model human diseases, it will also eliminate any ethical, moral and scientific issues involved with use of live humans and animals. An in vitro model, termed "MIMIC" (Modular IMmune In vitro Construct), was designed and developed to reflect the human immune system in a well-based format. The MIMIC System is a laboratory-based methodology that replicates the human immune system response. It is highly automated, and can be used to simulate a clinical trial for a diverse population, without putting human subjects at risk. The MIMIC System uses the circulating immune cells of individual donors to recapitulate each individual human immune response by maintaining the autonomy of the donor. Thus, an in vitro test system has been created that is functionally equivalent to the donor's own immune system and is designed to respond in a similar manner to the in vivo response.
Higbee
Russell G
RG
VaxDesign Corporation, Orlando, FL 32826-2784, USA. rhigbee@vaxdesign.com
Byers
Anthony M
AM
Dhir
Vipra
V
Drake
Donald
D
Fahlenkamp
Heather G
HG
Gangur
Jyoti
J
Kachurin
Anatoly
A
Kachurina
Olga
O
Leistritz
Del
D
Ma
Yifan
Y
Mehta
Riyaz
R
Mishkin
Eric
E
Moser
Janice
J
Mosquera
Luis
L
Nguyen
Mike
M
Parkhill
Robert
R
Pawar
Santosh
S
Poisson
Louis
L
Sanchez-Schmitz
Guzman
G
Schanen
Brian
B
Singh
Inderpal
I
Song
Haifeng
H
Tapia
Tenekua
T
Warren
William
W
Wittman
Vaughan
V
D000826:Animal Testing Alternatives; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000097:blood; D000942:Antigens, Bacterial / Q000008:administration & dosage / Q000276:immunology; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D004730:Endothelium, Vascular / Q000276:immunology*; D057166:High-Throughput Screening Assays; D006801:Humans; D007962:Leukocytes / Q000276:immunology*; D008221:Lymphoid Tissue / Q000276:immunology*; D018448:Models, Immunological; D013744:Tetanus Toxin / Q000008:administration & dosage / Q000276:immunology; D014612:Vaccines / Q000276:immunology*
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D013744:Tetanus Toxin; D014612:Vaccines